Lead multiple myeloma candidate enters Cohort 8; second asset dosed [...]
As global pharma grapples with shifting regulations, rising geopolitical tensions, [...]
Lead multiple myeloma candidate enters Cohort 8; second asset dosed [...]
As global pharma grapples with shifting regulations, rising geopolitical tensions, [...]